EGFR and non-small cell lung carcinoma: The aim of our study was to reveal the mechanism of ID1 mediated resistance to osimertinib in EGFR T790M-positive NSCLC through EMT, and to provide new ideas and methods for the clinical treatment of EGFR mutated NSCLC after osimertinib resistance.